Nonetheless, PAFAH1B2 expression has been reported as a prognostic marker for MM in validation analysis [41] while PTPN4 has been found to serve as an upstream therapeutic target in the treatment of prostate cancer [68], indicating the potential for the two proteins as future research entry points. Here, PAFAH1B2 is linked to prostate carcinoma.